Altimmune Set to Join Nasdaq Biotechnology Index Soon

Altimmune Joins Nasdaq Biotechnology Index

GAITHERSBURG, Md. — Altimmune, Inc. (Nasdaq: ALT), a dynamic clinical-stage biopharmaceutical company known for its innovative approach, is celebrating a significant milestone. The company has been recognized for its progress and will be officially added to the Nasdaq Biotechnology Index (Nasdaq: NBI) prior to the market opening on an upcoming Monday. This recognition not only highlights Altimmune’s achievements but also sets the stage for exciting developments ahead.

Significance of the Nasdaq Biotechnology Index

The Nasdaq Biotechnology Index is a prestigious index established in 1993, intended to monitor the performance of selected Nasdaq-listed stocks classified in the Biotechnology or Pharmaceutical sectors. Companies included in this index have to meet stringent eligibility criteria, such as market capitalization and trading volume, ensuring that only the most successful firms are represented. This index is evaluated annually and serves as the foundation for various investment funds, notably the iShares NASDAQ Biotechnology Index Fund (Nasdaq: IBB).

Company Reflection on Growth

Vipin K. Garg, Ph.D., President and CEO of Altimmune, expressed the enthusiasm shared by the team regarding their inclusion in the NBI. He stated, “Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company.” This sentiment reflects a year filled with critical advancements in their research and development efforts.

Looking Ahead: Major Developments

As we approach the new year, Altimmune is poised for significant developments. One of the most anticipated events is the release of topline data from the Phase 2b IMPACT trial of pemvidutide concerning metabolic dysfunction in MASH, expected in the first half of the upcoming year. This is just one of the key milestones that demonstrate the company's commitment to addressing pressing health concerns.

Pemvidutide: A Breakthrough Treatment

Pemvidutide stands out as a novel, investigational treatment that functions as a dual receptor agonist, targeting GLP-1 and glucagon receptors. This promising therapy aims to tackle obesity and MASH through a unique mechanism that replicates the effects of diet and exercise. By suppressing appetite and enhancing energy expenditure, pemvidutide is designed to provide an all-encompassing approach to weight loss.

Clinical Success and Future Trials

In ongoing clinical trials, pemvidutide has shown remarkable efficacy, resulting in substantial weight loss while preserving lean mass. Participants in these trials have also experienced notable decreases in triglycerides, LDL cholesterol, liver fat content, and blood pressure levels. With Fast Track designation granted by the FDA for treating MASH, the future looks promising for pemvidutide as it transitions into the next phases of clinical research.

About Altimmune

Altimmune is dedicated to pioneering cutting-edge therapeutics centered on peptide technology. Their commitment to medical innovation has put them at the forefront of biotechnology. With pemvidutide being developed for significant health issues, Altimmune continues to foster a culture of progress aimed at improving the lives of many.

Contact Altimmune

For inquiries, Altimmune’s Chief Financial Officer, Greg Weaver, can be reached at 240-654-1450 or via email at ir@altimmune.com. For further information about their initiatives, potential investors can reach out to Lee Roth at Burns McClellan, or media inquiries can be directed to Danielle Cantey of Inizio Evoke, Biotech.

Frequently Asked Questions

What is the Nasdaq Biotechnology Index?

The Nasdaq Biotechnology Index tracks the performance of Nasdaq-listed companies specifically engaged in biotechnology and pharmaceutical sectors.

Why is Altimmune joining the Nasdaq Biotechnology Index?

Altimmune's inclusion reflects its significant advancements and progress as a clinical-stage biopharmaceutical company.

What are the key developments Altimmune anticipates in the coming year?

Altimmune looks forward to crucial data releases from ongoing clinical trials, particularly involving their treatment pemvidutide.

What is pemvidutide?

Pemvidutide is a peptide-based treatment under investigation intended to help manage obesity and MASH by mimicking dietary effects.

Who can I contact for more information about Altimmune?

You can reach Altimmune’s CFO, Greg Weaver, at 240-654-1450 or email at ir@altimmune.com for inquiries regarding the company.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.